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ABSTRACT 
OBJECTIVE: 
To determine the association, if any, between certain risk factors for preeclampsia (PE) and 
the subsequent development of PE in a local cohort of South African women. 
 
DESIGN: 
A prospective study of women with any risk factor for PE for the duration of their pregnancy. 
 
METHOD: 
A prospective study was performed on selected women referred to Tygerberg Hospital, High-
risk antenatal clinic, with specific risk factors for the development of PE. A history-based 
questionnaire was completed by participants at enrolment and biophysical parameters were 
recorded at each subsequent antenatal visit, admission and at confinement. All data was 
captured according to the attached data sheet. All information was kept confidential and was 
strictly for the purposes of this study.  
 
STATISTICS: 
Statistics were performed using the SPSS statistics software version 17.0. Pearson Chi-square 
test of independence was used for correlating maternal historical factors, mean arterial 
pressures (MAP) and cardio-metabolic risk with the development of PE in the index 
pregnancy. p values were considered significant at values < 0.05.  
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RESULTS: 
The incidence of PE in the cohort was 11.4%. The age of the patient, parity, history of 
diabetes mellitus, MAP at booking and MAP at 24 weeks showed no significant association 
with the development of PE at any gestational age. There was a significant association 
between a history of PE in a previous pregnancy and the development of PE at any 
gestational age in the index pregnancy (p < 0.05). There were a significantly higher number 
of women with a history of chronic hypertension that developed PE in the index pregnancy (p 
< 0.0001). There were also a significantly greater number of obese women that developed PE 
at any gestational age in the index pregnancy (p < 0.05). The presence of any one or, a 
combination of cardio-metabolic risk factors was significantly associated with the 
development of PE at any gestational age (p < 0.005). 
 
CONCLUSION: 
The changing cardio-metabolic milieu, paralleling the pandemic in obesity, may be impacting 
on the development of PE. Screening for PE in South Africa may mean; validation of 
historical factors and MAP in prediction of PE in the local population, and if validated, 
incorporating it with the cardio-metabolic risk profile to triage women to appropriate levels 
of care. The pre-pregnancy, antenatal, postpartum and inter-pregnancy intervals can be used 
to optimise cardio-metabolic risk factors and these women, at the end of their reproductive 
careers, may benefit from life-long surveillance for cardiovascular disease. 
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Opsomming 
Doel: 
Om die assosiasie, indien enige, te bepaal tussen sekere risikofaktore vir pre-eklampsie (PE)1 en 
die daaropvolgende ontwikkeling van PE in ‗n lokale kohort Suid-Afrikaanse vroue. 
 
Ontwerp:  
‗n Prospektiewe studie van vroue met enige risikofaktor vir PE vir die duur van hul swangerskap. 
 
Metode: 
‗n Prospektiewe studie is uitgevoer op geselekteerde vroue wat na Tygerberg Hospitaal hoë risiko 
voorgeboortekliniek verwys is met spesifieke risikofaktore vir PE.  ‗n Geskiedenis gebaseerde   
vraelys is met werwing voltooi en biofisiese parameters is met elke daaropvolgende besoek, 
toelating en verlossing voltooi.  Alle data is volgens die datablad vasgelê.  Alle inligting is 
vertroulik hanteer en was spesifiek vir die doeleindes van die studie.   
 
Statistiek: 
Statistiese ontleding is met SPSS sagteware weergawe 17 uitgevoer.  Pearson chi-kwadraat  toets 
is gebruik om moederlike historiese faktore, gemiddelde arteriële druk (MAP) en kardio-
metaboliese risiko met die ontwikkeling van PE in die indeks swangerskap te korrelleer. p-
waardes < 0.05 is as betekenisvol beskou. 
 
                                                          
1
 PE = pre-eklampsie 
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Resultate: 
Die insidensie van PE in die kohort was 11.4%.  Die ouderdom van die pasiënt, pariteit, 
geskiedenis van diabetes mellitus, MAP met bespreking en MAP teen 24 weke 
swangerskapsduurte had geen betekenisvolle assosiasie met PE op enige swangerskapsduurte nie.  
Daar was ‗n betekenisvolle assosiasie tussen ‗n geskiedenis van PE in ‗n vorige swangerskap en 
die ontwikkeling van PE op enige swangerskapsduurte in die indeksswangerskap (p < 0.05).  
Daar was   betekenisvol meer vroue met ‗n geskiedenis van chroniese hipertensie wat PE 
ontwikkel het in die indeksswangerskap (p < 0.0001).  Daar was ook betekenisvol meer obees 
vroue wat PE in die indeksswangerskap ontwikkel het (p < 0.05).  Die teenwoordigheid van een, 
of ‗n kombinasie van kardio-metaboliese risikofaktore was betekenisvol geassosieer met die 
ontwikkeling van PE op enige swangerskapsduurte.  (p < 0.05).   
 
Gevolgtrekking: 
Die veranderende kardio-metaboliese milieu, met die pandemie van obesiteit, mag impak op die 
ontwikkeling van PE.  Sifting vir PE in Suid-Afrika mag beteken: bevestiging van historiese 
faktore en MAP in die voorspelling van PE in die plaaslike bevolking en indien bevestig, die 
insluiting van kardio-metaboliese risikoprofiel om vroue na toepaslike vlakke van sorg te stuur.  
Die pre-swangerskap, voorgeboortelike, postpartum, en inter-swangerskap intervalle kan gebruik 
word om kardio-metaboliese risikofaktore te optimaliseer en hierdie vroue mag aan die einde van 
hul reproduktiewe lewe baat by lewenslange opvolg vir kardiovaskulêe siekte.   
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  vi 
 
Acknowledgements 
 
Thank you to Professsor D.W.Steyn for his time and immense support in completing this 
dissertation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  vii 
 
Table of Contents 
 
Declaration……………………………………………………………………………………..i 
Abstract………………………………………………………………………………………..ii 
Opsomming…………………………………………………………………………………...iv 
Acknowledgements…………………………………………………………………………...vi 
Table of Contents…………………………………………………………………………….vii 
List of Figures……………………………………………………………………………….viii 
List of Tables…………………………………………………………………………………ix 
Chapter 1: Introduction……………………………………………………………………….1 
Chapter 2: Definitions and classification of hypertensive diseases of pregnancy……………4 
Chapter 3: Aetio-pathogeneses………………………………………………………………..7 
Chapter 4: Prediction of preeclampsia ….…………………………………………………...15 
Chapter 5: Preventative strategies……………………………………………………………25 
Chapter 6: Screening for preeclampsia in a South African setting…………………………..29 
Chapter 7: Study: Aims, Methods and Statistics…………………..…………………………31 
Chapter 8: Results………………………………………………………..…………………..33 
Chapter 9: Discussion………………………………………………………………...………35 
Chapter 10: Conclusion………………………………………………………………….…...38 
Appendix……………………………………………………………………………………..39 
Questionnaire and data sheet………………………………………………………………....43                             
References……………………………………………………………………………………49 
 
Stellenbosch University  https://scholar.sun.ac.za
  viii 
 
List of Figures 
 
Figure 1: Proportional representation of BMI categories in the cohort of women…………..40                                                      
Figure 2: Proportion of women with specific risk factors that developed preeclampsia in the      
               index pregnancy……………………………………………………………………42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  ix 
 
List of Tables 
 
Table 1: Association between specific risk factors and the development of preeclampsia in            
             the index pregnancy………………………………………………………………….41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  1 
 
CHAPTER 1 
INTRODUCTION 
 
The hypertensive disorders of pregnancy (HDP) are common. According to population-based 
data, 7–9% of pregnancies are complicated by hypertension1. Preeclampsia (PE) complicates 
approximately 3-5% of pregnancies worldwide
2
. 
HDP continues to rank among the top five causes of maternal death in South Africa (SA). 
HDP has been identified as the most common disorder causing morbidity, accounting for 
26% of severe acute maternal morbidity
3
. In addition, reports have confirmed that 
hypertension is the commonest reason for obstetric referral to an intensive care unit
4,5
. A 
review of all stillbirths and early neonatal deaths reported by the World Health Organisation 
(WHO) Calcium supplementation trial for the prevention of PE, conducted at centres in seven 
developing countries, showed hypertension to be the second commonest obstetric event 
leading to perinatal deaths, accounting for 23.6% of all perinatal deaths
6
. HDP, and in 
particular PE, remain a leading cause of adverse maternal and fetal outcomes
7-9
. 
HDP is heterogeneous in its classification and diagnostic criteria. There has never been 
consensus on the classification and diagnostic criteria for HDP. This has made comparison of 
data from different centres difficult and has negatively impacted on the body of evidence 
available to guide clinical management. The International Society for the Study of 
Hypertension in Pregnancy (ISSHP) attempted to ameliorate the problem by appointing a 
committee that reviewed available classifications and endorsed and published an international 
recommendation for how these disorders should be classified and diagnosed in pregnancy
10
. 
Since publishing this classification in 2001, much has changed in the realm of PE; its 
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proposed aetio-pathogeneses, models for screening and proposed preventative strategies. The 
ISSHP has since revised the classification, diagnosis and management of HDP
11
. 
 
Despite on-going research in the field of PE, the aetio-pathogeneses of this disease remains 
incompletely understood. Many theories have been proposed including; impaired 
trophoblastic differentiation and invasion, placental and endothelial dysfunction, immune 
maladaptation to paternal antigens and an exaggerated systemic inflammatory response
12
. PE, 
due to its heterogeneous nature, makes elucidation of the precise aetio-pathogeneses 
complex. The absence of precise aetio-pathogeneses has negatively impacted on the 
formulation of effective preventative strategies against the development of PE. Current 
interventions are being used in an attempt to correct theoretical pathophysiological 
abnormalities. Two such interventions are maternal dietary calcium supplementation and 
low-dose aspirin (LDA) prophylaxis. The reduction in the burden of disease with these 
prophylactic measures can be described as modest. 
 
We have also come to learn that PE has more than one phenotype and the disease has recently 
been described as ‗Pre-eclampsia: one name, two conditions‘13. A case has been made that PE 
presenting earlier in gestation differs in several ways compared to that which presents later in 
the pregnancy and it may actually be different disease entities. Evidence from 
epidemiological observations, clinical trials and biological studies seem to suggest that there 
may be different origins to PE presenting at different gestational ages with the early form of 
PE being associated with poor placentation and the late form of the disease being linked to an 
unfavourable maternal metabolic milieu
13,14
. 
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Having proposed different origins and phenotypes for PE it is very likely that prediction 
models, preventative measures and management strategies of the early versus the late forms 
of the disease may also differ.  
 
The disease entity remains unchanged but our fundamental understanding of the condition 
has changed and this requires a change in our mind-set to better manage this condition.  
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CHAPTER 2 
DEFINITIONS AND CLASSIFICATIONS OF HDP 
 
As previously alluded to; one of many factors contributing to the heterogeneity of HDP, and 
in particular PE, are the varying definitions and classification systems of the disease. The lack 
of consensus in this regard has retarded efforts to make research on the disease universally 
comparable and applicable. Steegers et al.
 
reviewed various classification frameworks and 
found the main differences were: (1) inclusion or exclusion of complicated non-proteinuric 
gestational hypertension (GH) as PE; (2) differentiation between clinical and research 
definitions; (3) use of early-onset PE as a severity criterion; (4) clinical importance of 
assessing white-coat hypertension; and (5) definition of severe hypertension
8
. 
The ISSHP in an effort to reach universal consensus on the definition and classification of 
HDP has updated its previous recommendation on how these disorders should be classified in 
pregnancy
10
. It has taken into account various existing classification systems, changes in 
clinical practice, recent developments and the growing knowledge of the aetio-pathogeneses 
of the disorder.  
The revised classification of HDP according to the ISSHP is as follows: 
1. Chronic hypertension, 
2. Gestational hypertension, 
3. Preeclampsia – de novo or superimposed on chronic hypertension, 
4. White coat hypertension
11
. 
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Definitions:  
PE and gestational hypertension are characterised by the new onset of hypertension (>140 
mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation
15.
 
GH is defined as the de novo development of high blood pressure after 20 weeks gestation, 
without any of the abnormalities that define PE, as listed below
11
. 
Chronic hypertension refers to high blood pressure predating the pregnancy
11
. 
PE refers to de novo hypertension present after 20 weeks gestation and the coexistence of one 
or more of the following new-onset conditions: 
1. Proteinuria (spot urine protein/creatinine >30 mg/mmol [0.3 mg/mg] or >300 mg/day or 
at least 1  g/L[‗2 + ‘] on dipstick testing) 
2. Other maternal organ dysfunction:   
 renal insufficiency (creatinine >90 µmol/L) 
  liver involvement (elevated transaminases – at least twice upper limit of 
normal ±    
 right upper quadrant or epigastric abdominal pain)  
 neurological complications (examples include eclampsia, altered mental 
status, blindness, stroke, or more commonly hyper-reflexia when accompanied 
by clonus, severe headaches when accompanied by hyper-reflexia, persistent 
visual scotomata)  
 haematological complications (thrombocytopenia –platelet count below 
150,000/dL, DIC, haemolysis)  
3. Utero-placental dysfunction  
 Fetal growth restriction11. 
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Pertinent points to emphasise about this classification are: 
 the demonstration of significant proteinuria is not a prerequisite for the 
diagnosis of PE, 
 there is no grading of hypertension into severe and non-severe forms,  
 hypertension in a patient who initiates antenatal care after  20 weeks of 
gestation with no previous blood pressure recordings shall be managed as GH 
or PE and investigations undertaken postpartum to exclude pre-existing 
chronic hypertension, 
 fetal growth restriction represents placental dysfunction and therefore forms 
part of the spectrum disorder of PE and, 
 the diagnosis of PE requires selected laboratory investigations. This may not 
be readily available in low resource settings which may result in the 
overburdening of higher levels of health care with referrals that in retrospect 
may have been unnecessary (particularly pertinent in a South African setting). 
This classification is by no means complete and unfortunately global consensus on a 
classification framework may never be achieved in the face of an evolving understanding of 
the disease process and dynamic research into prediction models, prophylaxis and optimal 
treatment strategies.  
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CHAPTER 3 
AETIO-PATHOGENESES 
 
Central to the understanding of current theories of the aetio-pathogeneses of PE is the 
appreciation that there is more than one phenotype of the disease. The evidence from 
biological, clinical and epidemiological studies
16-23
 support the view of essentially two 
phenotypes: placental, which usually occurs early in pregnancy and is associated with poor 
early placentation of different severity manifesting as a clinical spectrum of PE and/or 
restricted fetal growth; and maternogenic, which generally occurs late in pregnancy and it is 
not related to placental insufficiency and fetal growth restriction. Endothelial dysfunction is 
the final common pathway of the two postulated entities. The literature distinguishes early 
from late disease based on the gestational age at diagnosis, or, in some cases, gestational age 
at delivery with 34 weeks being the most used cut-off
8
. 
 
a) Early PE 
1. Normal pathophysiology 
1.1. The intervillus circulation 
The implantation of the embryo into the decidua occurs in a fairly avascular         
environment
24
. During this period extensive cytotrophoblastic proliferation occurs as 
opposed to cytotrophoblastic differentiation which is thought to be a process 
dependent on high oxygen tension
25
. The increased proliferative activity is thought to 
result in villus plugging of the terminal spiral arteries, inhibiting inter-villus 
perfusion. Remodelling of the maternal spiral arteries occurs between 8-10 weeks of 
Stellenbosch University  https://scholar.sun.ac.za
  8 
 
gestation and results in cytotrophoblastic unplugging and perfusion of the intervillus 
space. Increased oxygen delivery results in increased oxygen tension with 
consequences of oxidative stress and conversion of the cytotrophoblast into an 
invasive phenotype
24,25
. 
 
1.2. Remodelling of the Spiral Arteries 
Pre-pregnancy the spiral arteries are characteristically small, muscular arteries, richly 
innervated and sensitive to humoral and neural signals
23
. Between 10 and 20 weeks 
of gestation, these vessels are normally transformed, with a 5-10 fold increase in their 
intra-luminal diameter and elimination of the musculo-elastic components of the 
vessel wall resulting in flaccid and dilated vessels
26,27
. They lose all sphincteric 
function and their ability to respond to humoral and neural signals are blunted
23,28
.  
 
2. Proposed pathophysiology in early PE 
2.1  Remodelling of the spiral arteries.  
In women with early PE the spiral arteries fail to remodel and appear to maintain their 
pre-pregnancy characteristics. The consequences of this may be failure of the 
cytotrophoblastic unplugging with hypo-perfusion of the intervillus space but, more 
importantly, lack of spiral artery remodelling may fail to reduce the velocity of blood 
delivered to the intervillus space
23
. Burton et al. describe the major impact of the 
terminal dilatation of the spiral arteries is to reduce the velocity of the blood delivered 
to the intervillus space. This reduced velocity is essential to protect the delicate 
placental villi, which in the hemochorial placenta are in direct contact with the spiral 
artery blood flow. The reduced velocity of perfused blood is also necessary to allow 
time for the oxygen extraction. The potential consequence of failed terminal dilatation 
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is villus damage with an increased shedding of villus fragments into the maternal 
circulation and reduced oxygen extraction from the intervillus space. The villus 
damage is also proposed to lead to the release of procoagulants into the intervillus 
space with activation of the coagulation cascade, vascular occlusion, and placental 
infarction
23
. It has been postulated that the reduced oxygen extraction with the failed 
vascular remodelling, makes it highly possible that with an ischemic placenta, the 
blood in the intervillus space may actually be hyperoxic. The abnormalities in 
response to failed remodelling also result in oxidative stress secondary to a hypoxic 
reperfusion scenario
29
. 
 
What is the aetiology of lack of remodelling of the spiral arteries?  This question 
remains unanswered. One theory is based on the finding of reduced trophoblastic 
invasion together with failed spiral artery remodelling, making it likely that spiral 
artery remodelling is dependent on material produced by the trophoblast
26
. Another 
theory is based on the maternal-fetal immunological interaction. 
 
The hemochorial placentation brings the genetically different mother and fetus in 
intimate vascular contact with each when the trophoblastic cells invade the maternal 
spiral arteries
26
. This creates a potential immunological conflict between the mother 
and fetus. This theory is supported by the well-recognized protective effect of 
maternal exposure to paternal antigen prior to pregnancy. This theory would explain 
why primigravidae without prior exposure to fetal (paternal) antigens as part of the 
normal pregnancy associated intermingling of maternal and fetal (paternal) tissues, 
pregnancies occurring after only a brief exposure to paternal antigen, and the use of 
barrier contraception are associated with increased rates of PE
30
.  
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The case for angiogenic and anti-angiogenic factors playing a role in the defective 
trophoblastic invasion, differentiation and spiral artery remodelling is poorly 
supported.  It is proposed that the angiogenic factors, placental growth factor (PlGF) 
and vascular endothelial growth factor (VEGF), act to stimulate remodelling of the 
spiral arteries. It may superficially appear to play a causal role in defective early 
placentation, implicated in the pathogenesis of PE, as a relationship has been 
demonstrated between low PlGF concentrations and high concentrations of the decoy 
receptor for VEGF and PlGF, soluble fms-like tyrosine kinase 1 (s-Flt1), in PE, 
however the chronological sequence does not fit well to support this hypothesis. The 
higher concentration of s-Flt1 is not present until after the remodelling of the spiral 
arteries is proposed to take place
31
, while the concentrations of PlGF are minimally 
different at this time
32
.  
 
Other suggested mediators of vascular remodelling and trophoblastic invasion based 
largely on associations and in vitro experiments include uric acid and several 
cytokines and cytokine antagonists
33,34
. Ultimately, the pathogenesis of defective 
early placentation in PE remains to be fully understood. 
 
2.2 The effects of defective early placentation 
The main result of the defective placentation described above is that it renders the 
placenta ischaemic. There are both local and/or systemic consequences that ensue. 
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2.2.1 Local Effects 
2.2.1.1 Oxidative Stress 
As alluded to above, blood in the intervillus space is relatively hyperoxic, 
which exposes the fetal surface of the placenta to increased oxygen 
concentration, while at the same time, reduced extraction renders the 
majority of the placenta hypoxic. It is proposed that this combination and 
the residual responsiveness of the incompletely remodelled spiral arteries 
result in the generation of oxidative stress
35
. Oxidative stress occurs when 
the concentration of reactive oxygen species exceeds the buffering 
capacity of available antioxidants
36
. As a result of oxidative stress, the 
concentration of free radicals increases and free radicals associated with 
reactive oxygen species are extremely toxic and damage protein, lipids, 
and nucleic acids
36,37
 
 
2.2.1.2 Endoplasmic reticulum (ER) stress 
ER stress is a pathophysiological phenomenon closely linked with 
oxidative stress
38
. ER stress is a cellular mechanism to reduce protein 
synthesis in settings in which nutrient and oxygen delivery are insufficient 
to fully process proteins, resulting in a characteristic response, the 
―unfolded protein response‖ (UFR). With UFR, protein synthesis stops, the 
mechanism proposed for the genesis of small placentas with fetal growth 
restriction
37
. Under conditions of extreme stress, UFR can result in cellular 
apoptotic death. The release of inflammatory mediators, generation of 
reactive oxygen species, reduced protein synthesis, and the induction of 
apoptotic cell death have local as well as  a systemic impact
38
. 
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              2.2.2.  Systemic Effects 
The two-stage model of PE is that early defective placentation associated with 
failed spiral artery remodelling results in the release of placental products into 
the maternal circulation, which induces the pathophysiological features of PE. 
Oxidized lipids formed as a result of oxidative stress are incorporated into the 
membrane of the syncytiotrophoblast. The associated apoptotic effect of ER 
stress with the necrotic effects of oxidative stress and hypoxia augment 
structural changes secondary to oxidation to facilitate shedding of 
syncytiotrophoblast microparticles (STBM) into the maternal circulation. The 
STBM from the placenta associated with failed spiral artery remodelling 
contain oxidized lipids that are proposed to transfer oxidative stress 
systemically. In addition, in PE, an increased number of the particles that are 
released are necrotic rather than apoptotic and have toxic cellular effects that 
are not present with apoptotic particles
41,42
.The large number of STBM induce 
a more pronounced inflammatory response exacerbated by the qualitative 
changes of the particles that may also have additional toxic properties. 
Angiogenic and anti-angiogenic factors produced by the placenta are also 
influenced by hypoxia and oxidative stress
43
.The anti-angiogenic factor- s-Flt1 
is increased with hypoxia
43
. This decoy receptor sequesters the angiogenic 
factors, VEGF and PlGF, preventing interaction with their receptors
44
. It is 
also likely the PlGF production is also reduced since the circulating 
concentration of PlGF is lower in women destined to be pre-eclamptic prior to 
the increase in s-Flt1
45
. 
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b) Late PE  
Normal and preeclamptic pregnancies have been shown to be systemic pro-inflammatory 
states with features similar to those seen in sepsis
18,46
. Endothelial cells play a key role in 
intravascular inflammation by producing pro-inflammatory cytokines and stimulating 
leukocytes, platelets and other humoral components
47,48
. PE represents the exacerbation of 
these phenomena and the physiological changes that are present at term gestation closely 
resemble those seen in women with PE
18
. Factors proposed to mediate the inflammatory 
changes include: sFlt1 and STMP among others. They can be detected in the plasma of 
normal pregnant women and in even higher concentrations in the plasma of women with 
early PE
49
, but not usually those with late PE.  
What mediates the exaggerated systemic inflammatory response in late PE? It has been 
hypothesized that the presence of low-intensity pro-inflammatory factors derived from the 
placenta may exacerbate pre-existing low-grade chronic systemic inflammation caused by 
obesity or other conditions, resulting in a clinical condition termed maternogenic (late) PE
18
. 
Borzychowski et al., describe a concept of maternal PE as hypertension and proteinuria 
occurring in ―women with normal placenta, susceptible to systemic inflammation‖18. 
How does obesity and other components of the metabolic syndrome predispose to a systemic 
pro-inflammatory state? Adipose tissue is an active endocrine organ involved in nutrient 
homeostasis, immune response, blood pressure control, thyroid and reproductive function
19
. 
Adipocytes produce and release numerous biologically active substances, such as leptin, 
adiponectin, interleukins, tumor necrosis factor (TNF), interferon-γ and monocyte chemo-
attractant protein (MCP)-1, collectively termed adipokines
50
. Leptin and adiponectin, 
produced by white adipose tissue, have an opposite effect: adiponectin, has anti-inflammatory 
properties, and is reduced in obesity
51
, while leptin, a pro-inflammatory mediator, is 
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increased in obesity. As a result, cytokines, such as a MCP-1 and leptin, are secreted into the 
systemic circulation and act as strong chemo-attractant factors for the macrophages
52
. 
Macrophages present around adipocytes trigger a paracrine interaction loop with adipose 
cells
53
. Ultimately, this interaction will aggravate inflammatory changes in the adipose tissue 
and will further contribute to the release of pro-inflammatory cytokines in the circulation
54
 
resulting in endothelial activation and a systemic inflammatory response. Thus it is postulated 
that obesity and the metabolic syndrome can result in endothelial dysfunction and a 
hypertensive disorder, without or with minimal placental involvement. There may be overlap 
in the preeclamptic phenotypes with one or more of the pathogeneses implicated in a 
particular patient. 
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CHAPTER 4 
PREDICTION OF PE 
 
Having described the phenotypes of early and late PE and postulated different pathogeneses 
for the two entities, it would seem logical that the prediction of both phenotypes would also 
differ. Indeed this is the case, as I shall describe below, but the discussion on the prediction of 
PE would also be incomplete if the merit of screening for the condition is not elaborated 
upon. 
In 2004, Conde-Agudelo et al.
55
 conducted a large systematic review of predictive tests on 
behalf of the WHO. They identified over 50 screening tests in the published literature, of 
which many could be discounted because of low predictive values. The remainder were 
included in a meta-analysis that found that only uterine artery Doppler, anti-phospholipid 
antibodies and urinary kallikrein were of moderate predictive value in low risk women. The 
authors concluded that, as of 2004, there was ‗no clinically useful screening test to predict 
pre-eclampsia‘. They established desirable criteria for any future screening test:  
Simple,                                                                                                                                                           
Rapid,                                                                                                                                                                                                                
Non-invasive,                                                                                                                                                                                                                                
Inexpensive,                                                                                                                                                                       
Easy to carry out early in gestation,                                                                                                                         
Imposes minimal discomfort or risk,                                                                                                                                 
Widely available technology,                                                                                                                                      
Valid,                                                                                                                                                                               
Stellenbosch University  https://scholar.sun.ac.za
  16 
 
Reliable,                                                                                                                                                                     
Reproducible,                                                                                                                                                 
High likelihood ratio for a positive result (>10)  and                                                                                 
Low likelihood ratio for a negative result (<0.1)
55
. 
Since the establishment of these criteria there have been several tests and models proposed 
for the prediction of PE, but few that satisfy the above criteria and I shall therefore only 
review the most promising predictive tests in recent published literature. 
1. Should we offer universal screening for PE? 
A major role of antenatal care is to detect incipient PE and to prevent its 
progression
56
. The criteria presented above, proposed for any future screening test for 
PE, can only be met for screening performed in the first trimester. It is in this 
gestational window that the disease is in a latent form and is still amenable to the 
beneficial effects of available prophylactic measures
57-61
. 
 
Proponents for universal screening argue that screening in the first trimester includes 
a personalized risk estimate that is available to the entire obstetric population, with a 
97.5–99.8% certainty that PE will not occur in screen-negative women62 and the 
ability to evaluate the impact of preventive therapies on the observed-to-expected  PE 
rate, thus improving the statistical and clinical validity of intervention trials
63-65
. 
Opponents to universal screening for PE accede that first trimester screening is useful 
for the prediction of those who will ultimately progress to PE and require delivery at 
< 34 weeks of gestation
66
. They cite the following factors in counter argument to 
universal screening: the screening algorithms have low positive predictive values, 
ranging between 6% and 10%
66,67
 and limited validity in external populations
62,68
, 
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they preferentially predict early-onset disease with severe hypertensive features
69
 and 
there is an apparent absence of effective preventive interventions
66,67
. 
 
Baschat proposes that we improve the utility of the first trimester screen by using it to 
identify treatable conditions in screen-positive women, ‗as pre-eclampsia results from 
the convergence of multiple risk factors, evaluating the characteristics of women in 
whom prevention fails may point towards additional risk factors that require 
attention.‘70. 
 
2. Proposed screening strategies 
2.1. Maternal historical factors 
Factors that affect the risk of developing PE have been recognised since the 
beginning of the last century and include parity
71
, family history of PE
56,60
, diabetes 
mellitus
72
, chronic hypertension
73
, maternal age
56,74
, BMI
75
, ethnicity
76
 and 
socioeconomic status
56
. However it has only recently been possible to statistically 
estimate the individual risk that is attributable to each of the factors.
60,77,78
. The 
National Institute for Health and Clinical Excellence (NICE) guideline on routine 
antenatal care, recommends that at the booking visit a woman‘s level of risk for PE, 
based on factors in her history, should be determined and the subsequent intensity of 
antenatal care should be based on this risk
79
. However, there is no reference on the 
performance of such a recommended screening strategy, which treats each of the risk 
factors, as separate screening tests with additive detection and false positive rates
80
. 
Poon et al. showed that this strategy of treating each of the risk factors as separate 
screening tests would falsely classify two thirds of the obstetric population as high 
risk and in need of intensive monitoring
80. They further showed that ‗meaningful 
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screening for hypertensive disorders in pregnancy by maternal history necessitates 
the use of algorithms derived by logistic regression analysis‘ and that with such a 
strategy the estimated detection rates for early-PE, late-PE and GH are about 47%, 
41% and 31%, respectively, at a 10% false-positive rate
80
. This study suggested a 
methodology for deriving the a priori risk for early PE, late PE and GH based on 
maternal age, BMI, racial origin, history of PE and chronic hypertension and method 
of conception
80
. 
 
2.2.  First trimester uterine artery Doppler assessment 
As alluded to earlier, one of the key theories in the aetio-pathogenesis of early PE is 
defective placentation with impaired remodelling of the spiral arteries. Assessment of 
impedance to uterine artery blood flow by Doppler ultrasound, as first described by 
Campbell et al.
81
 serves as a surrogate marker of the degree to which successful 
spiral artery remodelling has occurred. Doppler studies of the uterine arteries at 11–
13 weeks have demonstrated that impedance to flow is increased in pregnancies that 
subsequently develop hypertensive disorders and that the increase is particularly 
marked for early PE
82-84
. The best performance of screening is provided by assessing 
the uterine artery with the lowest pulsatility index (L-PI)
84
. The estimated detection 
rate, at a 10% false-positive rate, in screening by a combination of the maternal 
factor-derived a-priori risk with uterine artery L-PI was 81% for early PE, 45% for 
late PE and 35% for GH
84
. It is as expected that this screening strategy would 
perform poorly for late PE based on the different aetiopathogenesis postulated for 
this phenotype. 
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2.3.  Mean arterial blood pressure (MAP) 
Various screening strategies for PE have been evaluated using various clinical 
parameters including diastolic blood pressure, systolic blood pressure, 24 hour 
ambulatory blood pressure and MAP. Cnossen et al.
85
 subjected these methods to a 
systematic review and found that MAP was a better predictor for PE than systolic 
blood pressure, diastolic blood pressure or an increase of blood pressure. Second 
trimester MAP of 90 mmHg or above showed a positive likelihood ratio of 3.5 (95% 
confidence interval [CI] 2 to 5) and a negative likelihood ratio of 0.46 (0.16 to 
0.75)
85
; falling far short of the desirable likelihood ratios for a predictive test
55
. The 
elevated MAP in pregnancies destined to develop PE may be an indicator of the 
cardiovascular risk profile of the patient. Once again, for maximum benefit from 
available preventative strategies for PE, a proposed screening test would have to be 
performed in the first trimester to be of value clinically. Poon et al.
86
 evaluated the 
performance of MAP at 11 weeks and 13 weeks and 6 days in combination with 
maternal variables in the prediction of PE and found that testing could, for a 10% 
false positive rate, identify 62.5% of those who would develop PE and 40% of those 
who would develop GH
86
. Unlike uterine artery Doppler, no difference was found in 
the ability of MAP to predict early PE over term disease
86
. More recently Gallo at et 
al.
87
 showed that the performance of screening for PE by MAP is best when 
measurements are taken at both 11-13 and 20-24 weeks' gestation than at only one of 
these gestational ranges. In screening at both gestational ages the DR at a FPR of 
10%, were 84.3, 65.7 and 52.5%; the DR at a FPR of 5% were 60.0, 49.7 and 37.6%, 
respectively
87
.  
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2.4. Biomarkers 
No individual biomarker has a predictive value sufficient for clinical prediction of 
PE
88
. Panels of tests have been shown to have better performance in the prediction of 
PE
88
. 
 
2.4.1. Markers of placental function 
Serum levels of pregnancy-associated plasma protein A (PAPP-A) and 
plasma protein 13 (PP-13) are have been shown to be reduced in the first 
trimester in women destined to develop PE
89-91
. PAPP-A is a protease 
derived from the syncytiotrophoblast and reduced serum levels may 
suggest either impaired function or a decreased cellular mass of this 
component of the placenta. PAPP-A also acts to cleave insulin-like growth 
factors (IGF) from their specific binding proteins, thereby increasing their 
mitogenic effect. The IGF family of proteins are believed to play a 
significant role in extravillus trophoblast migration and invasion, and 
therefore a reduction in the level of PAPP-A may reduce unbound 
available IGF at a cellular level and have functional effects
92
. PP 13, also 
produced by the syncytiotrophoblast, binds to proteins on the extracellular 
matrix between the placenta and the endometrium and is thought to play a 
role in placental implantation and maternal artery remodeling
93
.  Both 
markers are of predictive value; however, no additive effect was found in 
using both, probably because they both assess aspects of placental 
function
90
. In a combined screening model, PAPP-A in the first trimester 
was found to be significantly lower in early and late-onset PE, but not GH 
and contributed to the predictive ability of the model
94
.                                                               
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2.4.2 Angiogenic factors 
PlGF and VEGF are angiogenic factors. They play a central role in normal 
vasculogenesis in early pregnancy and later in normal maternal endothelial 
function
95,96
. They are inhibited by sFlt1. sFlt1 is a circulating anti-
angiogenic protein that adheres to the receptor binding domains of PlGF 
and VEGF, thus preventing interaction with endothelial cell receptors and 
leading to endothelial dysfunction
96
. Endoglin (sEng) acts in synergy with 
sFlt1 to exert their anti-angiogenic action
88
. PlGF levels are lower in the 
first trimester in women who subsequently develop PE
99
.  Free VEGF 
levels in serum are low as it has a higher affinity than PlGF for binding to 
sFlt1 making its detection technically difficult and discounting its clinical 
use as a predictive test
99
. Most studies have not shown any increase in 
sEng or sFlt1 levels before 16 weeks in women who subsequently develop 
PE
31,45,97,100
. 
 
2.5. Combined screening models 
There are many proposed combined screening models described in the literature. I 
shall elaborate on the most well studied and accepted. Poon et al.
94
 evaluated a large 
population (7797) of women with singleton, first-trimester pregnancies attending 
routine antenatal care, with an overall incidence of PE of 2%. The predictive model 
included: maternal variables (e.g. BMI, nulliparity or prior history of PE, ethnic 
origin), uterine artery Doppler, maternal MAP, PAPP-A and PlGF. For a 5% false-
positive rate, the sensitivity and specificity for early PE were 94.1% and 94.3%, 
respectively. The likelihood ratio for a positive test was 16.5 and the negative 
likelihood ratio was 0.06, meeting the screening criteria outlined previously.  
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More recently, Akolekar et al.
101
 investigated a model for prediction of PE based 
on maternal characteristics, biophysical and biochemical markers at 11–13 weeks‘ 
gestation in which the gestation at the time of delivery for PE is treated as a 
continuous variable. They showed that screening by maternal characteristics, 
biophysical and biochemical markers detected 96% of cases of PE requiring 
delivery before 34 weeks and 54% of all cases of PE at a fixed false-positive rate 
of 10%
102
. Wright et al.
60
 investigated a screening model for the prediction of PE 
based on maternal characteristics and biophysical markers at 11–13 weeks‘ 
gestation in which gestation at the time of delivery for PE is treated as a 
continuous variable. They found that screening by maternal characteristics, uterine 
artery PI and MAP detected 90% of PE cases requiring delivery before 34 weeks 
and 57% of all PE cases at a fixed false-positive rate of 10%
60
. 
 
In summary, it appears as if screening tests need to be performed early in gestation to be 
amenable to preventative strategies, they perform poorly individually and are better 
predictors of disease when combined screening strategies are employed, however; their 
positive predictive values remain low and they are generally better at predicting early than 
late disease. Sibai, in a recent commentary
66
 states that, ‗given the poor PPV for PE at < 34 
weeks, and the poor detection rates for all cases of GH/PE the clinical implications of a PE 
screen test in the first trimester remain unclear.‘.  
Baschat, in a recent editorial
70
, offers a novel approach to increasing the clinical utility of the 
first trimester screening test by not only using it to predict the personalised risk for PE but 
also to identify treatable conditions in screen positive women.  
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In the editorial
70
, Baschat refers to a study in which the rate of PE, despite the early initiation 
of LDA, was 9.3%
57
, much higher than the general obstetric population. He agrees that LDA 
does have limited efficiency but postulates that women may be developing PE because they 
have additional risk factors that are not addressed by LDA. There are studies that indicate that 
women at high risk for PE, and in whom LDA fails, are more likely to have chronic 
hypertension, with a higher blood pressure at enrolment, pre-existing diabetes and an 
increased BMI
64,102
. It would appear that the cardiovascular and metabolic risks for PE are 
not addressed by current prophylactic measures, as expected from the proposed aetio-
pathogeneses, and that these women go on to develop PE. 
2.6.  Cardiovascular, metabolic and prothrombotic risk profiles 
Scholten et al.
103
 evaluated the prevalence of cardiovascular, metabolic and 
prothrombotic risk profiles in women with a prior history of PE. They identified that 
77% of women had at least one risk profile. Of these, the cardiovascular risk profile 
was most prevalent (66.1%), followed by hyperhomocysteinemia (18.7%), metabolic 
syndrome (15.4%) and thrombophilia (10.8%).  
 
The components included in the prediction rules of first trimester multivariable 
predictive models are typically categorised as maternal historic factors, maternal 
physical characteristics, uterine artery Doppler studies and biomarkers
60,67,77,101
. 
Within these categories multivariate prediction models identify maternal BMI, 
hypertension, prior PE, MAP, uterine artery Doppler and biomarkers among the top 
ten independent predictors of PE
101,104-111
. Baschat
70
, proposes an alternate way to 
categorize these screening variables is by their representation of risk profiles. A prior 
history of hypertension, renal disease and elevated blood pressure can be considered 
as representative of a cardiovascular risk profile, while increased BMI, prior diabetes 
Stellenbosch University  https://scholar.sun.ac.za
  24 
 
or gestational diabetes represent a metabolic risk profile and a history of 
thrombophilia represents a prothrombotic one
70
. He suggests that this categorization 
has the advantage of allowing estimation of the contribution of treatable conditions to 
a woman‘s personalized PE70. 
 
2.6.1. The metabolic risk profile 
Pregnancy is a state of relative insulin resistance and each additional component 
of the metabolic syndrome has been shown to increase the risk of PE by 30-
40%
112,113
. Metabolic syndrome features that persist after pregnancy, increases 
the recurrence of PE up to three-fold with each additional component of the 
metabolic syndrome present, with hypertension and hyperinsulinemia as the 
leading risk factors
114
. Theoretically, optimisation of the metabolic profile pre-
pregnancy or early in the gestation may decrease the risk of the development of 
PE and also have long term health benefits for the patient. 
 
2.6.2. The cardiovascular risk profile 
As alluded to earlier, several first trimester screening algorithms identify 
hypertension in the first trimester as the most prevalent and consistently 
demonstrated, independent risk factor for the development of PE. Thresholds for 
the treatment of hypertension in the first trimester remain controversial. First-
trimester, observational data indicate that high-risk women who are 
normotensive in the first trimester have a 50% reduction of PE, while those with 
pre-hypertension or hypertension have a greater than two-fold increased risk
64
. 
Addressing chronic hypertension prepregnancy or in early pregnancy may be the 
key to significantly impacting on the development of PE.  
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CHAPTER 5 
PREVENTATIVE STRATEGIES 
 
There have been a host of therapeutic interventions proposed over the decades for the 
prevention of PE, most with disappointing outcomes. The hope of elucidation of the precise 
aetiopathogenesis and a better understanding of the disease process holds the hope of 
discovering more promising prophylactic strategies.  
I shall further elaborate on the most successful prophylactic measures to date and also 
provide an insight into what lies ahead in this field.  
1. Low Dose Aspirin 
As previously alluded to, pathologic findings associated with the PE include defective 
remodelling of the spiral arteries, activation of the clotting system, and imbalances of 
prostacyclin and thromboxane
115
. Based on these findings, LDA, an antiplatelet agent, 
thought to restore prostacyclin and thromboxane levels and prevent vasoconstriction, 
has been targeted as an intervention to reduce PE in at-risk women
116,117
. Large RCTs 
investigating the benefit of aspirin prophylaxis have demonstrated either a very 
modest reduction in PE risk
116
 or more commonly no significant benefit at all
115, 118-
123
. The PARIS Collaboration utilized individual patient data in a meta-analysis that 
demonstrated a statistically significant 10% reduction in risk
124
 and this has been 
supported by similar findings in a Cochrane review
125
. The validity of meta-analyses 
on this topic has come into question as it is thought to be limited by the inclusion of 
small reports subject to publication bias that may over estimate effect size, if 
present
124
.  Bujold et al.
57
, in a subgroup meta-analysis, investigated the benefit of 
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LDA started at 16 weeks or earlier and showed a major benefit with up to 50% 
reduction in PE and fetal growth restriction. Once again one needs to be wary of bias 
in subgroup meta-analyses
126
.  
 
2. Calcium 
Low dietary calcium intake has been associated with an increased risk of developing 
PE
127
. A large RCT found no benefit from calcium supplementation in terms of risk 
reduction of the incidence or severity of PE.  There were no differences in the number 
of preterm deliveries, small-for-gestational-age births, or timing of onset of 
hypertensive diseases
128
. This is in contrast to the RCT conducted by the WHO which 
showed that in nulliparous women with low dietary calcium intake, calcium 
supplementation did not reduce the primary outcome of incidence of PE however it 
did reduce some secondary outcome measures including maternal and neonatal 
morbidity
129
. It can be concluded that calcium supplementation for PE prophylaxis is 
not indicated in calcium replete populations but there may be some benefit derived, in 
terms of reduced maternal and neonatal morbidity, from calcium supplementation in 
calcium deplete populations. 
 
3. Vitamin C and E 
Vitamin C and E have been investigated for the prevention of PE, based on their 
known antioxidant properties and the proposed theory that PE may arise as a result of 
a process of oxidative stress. The VIP trial evaluated the supplementation of vitamins 
C and E in the prevention of PE and found no risk reduction associated with vitamin 
supplementation
128
. These findings were subsequently confirmed by large RCTs
129,130
. 
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4. Prophylactic interventions under investigation 
4.1.Statins 
Statins were listed as Food and Drug Administration Category X primarily 
because of theoretical concerns regarding inhibition of cholesterol formation 
during fetal development and, in addition, until now there have been no specific 
indications for use of this class of drugs in pregnancy. However, subsequent data 
on pravastatin, lovastatin, and simvastatin have not demonstrated these drugs to be 
associated with increased risk for congenital malformations or adverse 
outcomes
131
. Statins have demonstrated effectiveness in counteracting the 
angiogenic imbalance, endothelial damage, oxidative stress, and inflammation 
implicated in the pathogenesis of PE
132
 and this has been supported from animal 
model research into PE
133,134
. Currently a double-blind, placebo-controlled pilot 
study is underway to collect safety and pharmacokinetic data for pravastatin use 
during high-risk pregnancies
135
.  
 
4.2.Metformin 
The issues surrounding hyperinsulinaemia and insulin resistance could possibly be 
addressed by the administration of Metformin. A recent meta-analysis of women 
with polycystic ovary syndrome who continued therapy after conception showed 
that metformin reduced PE by almost 50%, with a pooled odds ratio of 0.53 (95% 
CI, 0.30–0.95)136. Metformin may also have benefits of an improved 
uteroplacental circulation as demonstrated in the reduced uterine artery impedance 
in the second and third trimesters in women taking metformin during 
pregnancy
137
.  
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4.3.Folate 
Higher plasma homocysteine levels, in early pregnancy, increase the risk of PE 
three to four-fold
138,139
. Increased homocysteine levels are significantly more 
common in women who develop PE and low dietary folate is an important 
contributor to this
140
. Modification of homocysteine levels requires high-dose 
folate and a randomized trial evaluating a daily folate dose of 4 mg is currently 
underway
141,142
. 
 
4.4.Lifestyle modification 
Optimisation of risk factors preconception may hold the key to optimising 
outcomes in pregnancy. In women with diabetes and one factor of maternal 
vascular disease, there is a 25% risk of PE and fetal growth restriction; good 
glycaemic control modifies this risk
143
. Obesity is known to be a risk for both PE 
and gestational hypertension; with morbid obesity (BMI of > 35) the odds ratio for 
PE is 7.2
144
. Weight loss in overweight and obese women before pregnancy may 
modify these risks but remains to be demonstrated in well-designed studies. 
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CHAPTER 6 
SCREENING FOR PE IN A SOUTH AFRICAN SETTING 
 
PE is now better conceptualised as a spectrum disorder as it may clinically manifest as more 
than one phenotype and sometimes with overlap among the various phenotypes. There are 
currently many theories on the aetio-pathogeneses of PE and again, they vary according the 
different phenotypes.  Many predictive tests have been described but few that meet 
recommended criteria for a screening test for PE. There has been a gradual move toward 
combined screening algorithms, to increase detection rates, early in pregnancy, when 
prophylactic intervention may still have meaningful impact. There are many arguments in 
favour of, and against the routine screening for PE in pregnancy, but one that stands out is the 
low positive predictive values of individual and/or combined screening algorithms. 
Increasing the utility of first trimester screening tests by incorporating cardio-metabolic and 
thrombotic risk profiling has been proposed. This may have advantages of being able to 
modify risk factors early in gestation, deciding on the appropriate level of care for the 
woman, and may translate into optimal health care for long-term cardiovascular health 
surveillance and early detection and treatment of disease. Unfortunately, there is little in the 
way of PE prophylaxis available. LDA, and perhaps calcium in certain populations, show the 
most promising results to date. There are however many trials on-going, looking especially at 
ways of ameliorating the cardio-metabolic risk associated with the development of PE. 
Many factors need to be incorporated when thinking of screening for PE in SA, among them:  
- Competing interests for limited resources 
- The poor socio-economic make-up of the majority of the population 
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- The changing face of PE in the background of a population in which 42% of women 
have been recorded as obese
145
. 
- The rising cardiovascular and metabolic related morbidities paralleling the rising rate 
of obesity and impacting on the incidence and phenotype of PE and affecting long 
term health. 
 
The existing screening models have not been validated in local populations and all the 
components of suggested screening models may not be feasible in a resource constrained 
setting. Common practice in many SA health institutions is to refer any patient with historical 
risk factors for PE to a higher level of care for further ante-natal care. The implication of this 
practice is that the majority of women will not go on to develop PE resulting in the 
overburdening of already strained health care services, usually these women are expected to 
have many health care visits placing greater financial burden on the women and the 
unnecessary medicalization of a large number of pregnancies. What factors, in a local 
population of pregnant women, are associated with the development of PE? 
We performed a prospective study of women referred to the antenatal clinic at Tygerberg 
Hospital (a level 2 hospital in the Western Cape, SA), following a positive historical screen 
for PE, and determined specific pregnancy outcomes based on certain risk factors for PE.  
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CHAPTER 7 
STUDY: A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF 
SPECIFIC RISK FACTORS WITH THE DEVELOPMENT OF PREECLAMPSIA. 
Aim: 
To determine the association, if any, between certain risk factors for PE and the subsequent 
development of PE in a local cohort of South African women. 
 
PATIENTS AND METHODS 
After institutional ethical approval was obtained, all women referred to Tygerberg Hospital 
High Risk antenatal clinic, following a positive maternal historical screen for PE, were 
screened for eligibility for the study. Inclusion criteria were a singleton pregnancy with a 
positive maternal historical screen for PE (a positive screen included any one of the 
following: age < 18 years old, age > 37 years old, nulliparity, grande-multiparity, history of 
PE, chronic hypertension, chronic renal disease, gestational diabetes mellitus (GDM), pre-
gestational diabetes mellitus (DM) or BMI ≥ 30) and a gestational age of < 20 weeks (by last 
menstrual or an early ultrasound). All women with a non-viable pregnancy, early pregnancy 
loss or intra-uterine fetal death diagnosed at the first antenatal visit were excluded. Women 
meeting the criteria were informed about the study and written consent was obtained prior to 
enrolment. All women enrolled in the study (n=299) over the 2 year period were assisted in 
completing a questionnaire (Appendix) at enrolment regarding their family, social and 
obstetric history. Their scheduled frequencies of visits to the antenatal clinic were as per 
standard protocol, and specific data were recorded on a data sheet (Appendix) at each 
antenatal visit until discharge from hospital, post-delivery.  
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Data were entered into a database and analysed retrospectively. Data included maternal age, 
race, parity, history of gestational diseases (PE, GDM), chronic diseases (hypertension, renal 
disease, DM, and autoimmune diseases), smoking history, BMI on first antenatal visit, MAP 
at first antenatal visit and at 24 weeks gestation and pregnancy outcomes (development of 
early PE (onset <34 weeks gestation) and late PE (onset ≥ 34 weeks gestation). 
Points studied were the association of maternal historical factors, MAP and cardio-metabolic 
risk (chronic hypertension and/or chronic renal disease and/or diabetes mellitus and/or 
obesity) with the development of early PE , late PE and PE at any gestational age in the index 
pregnancy.  
Statistics were performed using the SPSS statistics software version 17.0. Pearson Chi-square 
test of independence was used for correlating maternal historical factors, MAPs and cardio-
metabolic risk with the development of PE in the index pregnancy. p values were considered 
significant at values < 0.05. 
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CHAPTER 8 
RESULTS 
 
The mean age of all women was 31 +/- 6.7 years. Women under the age of 18 years made up 
2% of the cohort, while women from 18 years to 37 years of age and women > 37 years of 
age made up 77% and 21% of the cohort, respectively.  The ethnic make-up of the cohort was 
predominantly Coloured (90.3%) and African (8%). Nulliparous women accounted for 23% 
of the cohort, women with a parity of 1 – 4 comprised 72% of the cohort and 5% of women 
had a parity of ≥ 5. Of all women, 21.4% had a history of PE, 17.4% had a history of chronic 
hypertension and 13.4% of the women were known with DM. There were only 2 women in 
the cohort with chronic renal disease. 30% of the women had a positive smoking history.  
The average gestational age at booking, in the index pregnancy, was 11 weeks and 4 days. 
The average BMI was 30.38 +/-7.8 kg/m
2, with 49.2% of women being obese (BMI ≥ 30). 
The proportional representation of women in the various BMI categories is presented in 
Figure 1 (Appendix). The incidence of PE in the cohort was 11.4% of which 6.7% was early 
and 4.7% was late PE.  
Data of ethnic groups and history of chronic renal disease were not analysed as the specific 
categories were over and under-represented, in the cohort, respectively. The age of the 
patient, parity, history of PE, chronic hypertension, DM, obesity, MAP at booking and MAP 
at 24 weeks gestation showed no significant association with the development of either, early 
or late PE. The age of the patient, parity, history of DM, MAP at booking and MAP at 24 
weeks showed no significant association with the development of PE at any gestational age.  
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There was a significant association between a history of PE in a previous pregnancy and the 
development of PE at any gestational age in the index pregnancy (p < 0.05). There were a 
significantly higher number of women with a history of chronic hypertension that developed 
PE in the index pregnancy (p < 0.0001). There were also a significantly greater number of 
obese women that developed PE at any gestational age in the index pregnancy (p < 0.05). Of 
note is that obese women were more likely to be diagnosed with chronic hypertension in the 
index pregnancy (n = 24, p < 0.0001). The presence of any one or a combination of cardio-
metabolic risk factors was significantly associated with the development of PE at any 
gestational age (p < 0.005). Results are presented in Table 1 (Appendix) and Figure 2 
(Appendix).  
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CHAPTER 9 
DISCUSSION 
 
A major role of antenatal care is to detect incipient PE and to prevent its progression
56
. In SA, 
a community-based study found a 12% incidence of HDP in KwaZulu-Natal
146
, while a 
tertiary facility-based study reported a rate of prevalence of 18%
147
.  Our study found an 
incidence of 11.4%, specifically for PE. Most would agree that this represents an important 
health problem to warrant screening and early intervention. A major challenge in a 
developing country, like SA, is what would be meaningful, yet feasible, screening and 
preventative strategies to employ? Major factors to be incorporated when thinking of PE 
screening strategies in SA are; competing interests for limited resources, poor socio-
economic make-up of the majority of the population, the impact of the obesity pandemic on 
PE (42% of South African women have been found to be obese
145
) and the rising 
cardiovascular and metabolic related morbidities, paralleling the rising rate of obesity, 
impacting on the incidence and phenotype of PE and affecting long term health.  
The existing screening models have not been validated in local populations and all the 
components of suggested screening models may not be feasible in a resource constrained 
setting. Realistically, components of the suggested first trimester PE screen that may be 
feasible, in the South African public sector, are the maternal historical factors and MAP 
assessment. Serum biomarkers and uterine artery Doppler screening can be discounted as 
screening tests locally, mainly due to the high cost implications and need for a large number 
of expertly trained personel in the field. Pregnancy, for many women in SA, may be their 
only opportunity to be screened for disease and so apart from using pregnancy to screen for 
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PE, the screen may serve a greater purpose; to optimise risk factors for the index pregnancy, 
future pregnancies and for the short and long term health of women in general.  
Our study, although not aimed to validate maternal historical factors in predicting the 
development of PE, does seem to suggest that, with the exception of a history of previous PE, 
maternal historical factors may not be the most important factors in risk categorising women 
in our population. This would however need validation in a larger study before any firm 
conclusions can be drawn. Is obesity with its attendant co-morbidities becoming the prime 
predictor for adverse pregnancy outcome in our population? Our study underscores the 
impact of obesity and cardio-metabolic risk on the development of PE. The study has 
demonstrated significant associations between the presence of one or more cardio-metabolic 
risk factors and the development of PE. Taking into consideration the pathophysiological 
mechanism whereby the cardio-metabolic milieu is proposed to influence the development of 
PE, one may reason that current preventative strategies (LDA and Calcium) may not be as 
effective in a population like ours and that there are perhaps other risks that need to be 
addressed. Our study also highlights the burden of cardio-metabolic risk in our antenatal 
clinic (overweight and obese women, together,  making up 72 % of the cohort) and together 
with its significant association with the development of PE, a  setting like ours,  may serve as 
fertile ground for research into disease modifying interventions, like the use of statins, 
metformin and lifestyle modification.  
 
It is not particularly surprising that none of the risk factors were significantly associated with 
the development of either early or late PE, when examined as separate entities. With the high 
prevalence of cardio-metabolic risk factors in the cohort, it was not uncommon to find that 
women often, had more than one risk profile and often a high risk profile for the development 
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of early and late PE was present in the same patient. This apparent overlapping of risk 
profiles would make the prediction of early versus late PE difficult and whether this 
knowledge (risk of developing early vs. late PE) would contribute further to the care of 
women in a developing country is debatable, as the women would, in any case, have been 
triaged to a higher level of care based on her initial positive screen for PE. 
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CHAPTER 10 
CONCLUSION 
 
In conclusion, screening for PE in SA may mean; validation of historical factors and MAP in 
prediction of PE in the local population, and if validated, incorporating it with the cardio-
metabolic risk profile to triage women to appropriate levels of care.  Women categorised as 
high risk can receive LDA and calcium prophylaxis, have their cardio-metabolic risk 
optimised, and have increased surveillance for the development of PE. The postpartum and 
inter-pregnancy intervals can be used to further optimise cardio-metabolic risk factors and 
these women at the end of their reproductive careers may benefit from life-long surveillance 
for cardiovascular and metabolic disease. We need integrated programs aimed at schooling- 
going children to prevent obesity and in reproductive aged women  to modify their cardio-
metabolic risk which may positively impact on the development of PE and its complications, 
and improve the long-term cardiovascular health of women in general.  
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Figure 1. 
Proportional representation of BMI categories in the cohort of women. 
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Table 1. 
Association between specific risk factors and the development of PE in the index 
pregnancy. 
 
 
 
 
 
 
 
Total number of 
patients (n) 
Number who 
developed PE in the 
index pregnancy (n) 
p value 
History of PE 64 13 0.01 
Chronic hypertension 48 14 0.000 
Obesity 147 23 0.02 
1 or more 
cardiometabolic risk 
factors 
 
177 
 
27 
 
0.003 
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Figure 2. 
Proportion of women with specific risk factors that developed PE in the index 
pregnancy. 
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A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF SPECIFIC 
RISK FACTORS WITH THE DEVELOPMENT OF PREECLAMPSIA (PE). 
Questionnaire 
 
 
 
 
Risk factor …………………………………………………………………………………. 
Gravidity………………………….             Parity………………………. 
Previous Pregnancies 
 Pregnancy 1 Pregnancy 2 Pregnancy 3 Pregnancy 4 Pregnancy 5 
Year      
Gestation at 
delivery 
     
Baby Wt (kg)      
Mode of 
Delivery 
     
Complications      
Outcome      
Consort 
number 
     
 
Describe any complications: 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Medical History: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………. 
 
 
 
PLACE PATIENT STICKER HERE 
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Medication: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
……………………………………………………………………………………………….... 
Surgical history: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Allergies: 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Smoker (cigarettes/day): …………….                            Cans of cooldrink/day: …………… 
Personal History 
Birth place: ………………………………………………. 
Any complications with your birth? 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Menarche (age)……………………………..                   Menarche (year) …………………. 
LNMP………………………………………                   No. of days………………………... 
Duration of relationship with partner…………………………………………………………. 
Previous children with other partner(s)……………………………………………………….. 
Contraception (Y/N)…………… 
When did you stop before current pregnancy………………………………………………….. 
Types of contraceptives and duration………………………………………………………….. 
Ever use condoms?.......................................                       How long?.................................... 
Until when? ………………………………… 
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History of father of this pregnancy 
DOB:……………………………………                            Birth place……………………… 
Any health problems: 
………………………………………………………………………………………………… 
Any children with another partner?.................................................... 
Any complications with the birth of those children?.................................................................. 
History of your mother 
How old is your mother?..........................                    
Any illnesses?............................................................................................................................. 
Medications:……………………………………………………………………………………. 
Operations:…………………………………………………………………………………....... 
Weight (kg)……………………………                            Height (m)…………………………. 
Number of pregnancies………………..                            Live births ………………………… 
Miscarriages………………………….. 
Problems with pregnancies 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
History of your sisters 
Number of sisters?.........................                                 How many were ever pregnant?........ 
How many had hypertension in pregnancy?.................................................... 
How many had miscarriages?..................................................... 
How many had still born babies?................................................ 
Details…………………………………………………………………………………………
………………………………………………………………………………………………… 
Do your sisters have any illnesses ? 
......................................................................................................................................................
...................................................................................................................................................... 
Do they use any medication ? 
…………………………………………………………………………………………………
……………………………………………………………………………………………….... 
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DATA SHEET 
Medical examination on booking: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Weight (kg) …………………….                                          Height (m) …………………… 
Routine tests: 
RPR:……………………..                                                     Blood group: …………………… 
Urine MCS: ……………………                                           PAP smear: …………………….. 
HIV: …………………………...                                           Hb: ………………….. 
Other tests: 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Sonar: 
Date:  ………………………………….                 Gestational age: ………………………… 
Placenta: ……………………………… 
Other: 
………………..............................................................................................................................
......................................................................................................................................................
......................................................................................................................................................
..................................................................................................................................................... 
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Antenatal consultations: 
Date       
SFH       
SBP       
DBP       
Proteinuria       
Glucosuria       
Oedema       
FBC       
Hb       
Complaints       
Admission       
Doppler       
Other       
       
       
 
Describe any complaints or complications 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Patient admitted before onset of labour (Y/N) ………………………… 
Reason for admission: 
…………………………………………………………………………………………………
………………………………………………………………………………………………….. 
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Confinement: 
Date: …………………….                                                   Gestation: ……………………… 
Weight (g) ………………….                                              Sex: ……………………………. 
APGAR ………….                             ………………………                    …………………. 
Mode of delivery …………………………………                     Reason……………………. 
SROM (Y/N) ………………………                                    Gestation …………………….. 
IOL (Y/N) ………………………….                                    Method ……………………….. 
Indication ………………………….. 
Abruptio Placentae (Y/N)………………………………….. 
Placental mass (g) …………………………………………. 
Other significant info. 
……………………………………………………………………………………………… 
Baby outcome (alive, SB, miscarriage, neonatal death)…………………………………… 
Days in hospital:………………………………     Admiission to NICU (Y/N) …………. 
Complications during pregnancy:…………………………………………………………. 
…………………………………………………………………………………………….. 
PE (Y/N)……………………                                  Grade: ………………………………. 
GA at diagnosis ………………………………………………… 
Admission to Special Care (Y/N) ………………………………. 
Hypertension without PE (Y/N) ………………………………… 
Anti-hypertensive medication 
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
Any other complications: 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
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